-
MedPAC: It's the Drug Prices, Stupid Opens in a new window)
MedPAC has argued for Medicare drug pricing reforms for several years, and federal agencies often take their recommendations seriously. But industry opposition has been the primary roadblock to several MedPAC proposals. -
Biden's Biomedical Research Agency Dropped From Social Spending Bill Opens in a new window)
Some research advocates fear the Advanced Research Projects Agency for Health could be left behind in a crush of end-of-session business and lose momentum.Comments
-
Sanofi, GSK Can't Escape Zantac Proposed Class Actions, Judge Rules Opens in a new window)
The lawsuits are part of the broader multidistrict litigation over Zantac and ranitidine after various drugmakers including the defendants launched recalls of their products in 2019.Comments
-
Drug Price Negotiation Doesn’t Mean the Government Will Restrict Access to Medicines Opens in a new window)
In fact, the proposed drug price negotiation program does not authorize the federal government to decide which medications people on Medicare can and cannot get and does not establish or require a particular prescription drug formulary.Comments
-
Biosimilars Competition Helps Patients More Than Generic Competition Opens in a new window)
A notion in the policy community is that competition between biologics and their biosimilars does not save patients and taxpayers as much as well-functioning generic competition.Comments
-
Bernie Sanders Isn't Holding Back Anymore, Accusing Sinema and Manchin of Selling Out Biden's Agenda to Big Pharma Opens in a new window)
In his latest press conference, he implied their policies are linked to donations from big pharmaceutical firms.Comments
-
Sen. Bob Menendez’s Opposition to Drug Pricing Reform May Imperil the Democratic Agenda Opens in a new window)
The New Jersey Democrat refuses to say whether his resistance to Medicare drug bargaining will turn him against the reconciliation bill.Comments
-
A Federal Drug Purchasing Program Could Save Billions Opens in a new window)
Medicare and a host of other federal agencies are prohibited by law from accessing this kind of purchasing power.Comments
-
'Entirely Unsurprising': Merck Slammed for 4,000% Markup of Taxpayer-Funded COVID-19 Drug Opens in a new window)
"Another example of Big Pharma reaping billions from public investment into research".Comments
-
Europe’s Largest Clinical Trial Sponsors Are Getting Better at Reporting Results Opens in a new window)
The 26 research institutions have run nearly 4,600 trials testing medicines and, so far, 641 sets of results have been made available.Comments
-
AbbVie Loses a Lawsuit Over Humira Trade Secrets it Claimed Were Stolen Opens in a new window)
A U.S. federal court judge dismissed a lawsuit in which the drug maker claimed a would-be rival hired one of its employees, who then allegedly transferred a boatload of confidential information about its best-selling Humira treatment.Comments
-
US FDA Unlikely To Issue Broad Biosimilar Guidance Saying Comparative Clinical Studies Unnecessary Opens in a new window)
OTBB head Sarah Yim says FDA internal thinking is not aligned on the idea and that a lot of convincing was necessary to drop the clinical study requirement for insulin biosimilars.Comments
-
Vancouver Votes to Support Application That Would Create Safe Drug 'Compassion Clubs' Opens in a new window)
Vancouver City Council has voted to support a federal application that would allow a "compassion club" model and provide tested drugs in the city.Comments
-
Africans Welcome New Malaria Vaccine. But Is It a ‘Game Changer'? Opens in a new window)
When babies are born in western Kenya, where malaria is rife, many mothers are sent home from the hospital with one all-important baby gift: a bed net treated with insecticide.Comments
-
Government Price Controls Will Kill Pharma Innovation, Lilly CEO Says Opens in a new window)
America is the cradle of breakthrough pharmaceutical innovation. U.S. biopharmaceutical companies create nearly two in every three new medicines.Comments
Comments